Obese children with ALL are likely to be at higher risk for treatment-related toxicities, such as steroid-induced hyperglycemia, asparaginase-induced pancreatitis, hepatic steatosis and osteonecrosis [45, 46]. This evidence concerns the gene ASPG and osteonecrosis.